JP2005533050A5 - - Google Patents

Download PDF

Info

Publication number
JP2005533050A5
JP2005533050A5 JP2004511275A JP2004511275A JP2005533050A5 JP 2005533050 A5 JP2005533050 A5 JP 2005533050A5 JP 2004511275 A JP2004511275 A JP 2004511275A JP 2004511275 A JP2004511275 A JP 2004511275A JP 2005533050 A5 JP2005533050 A5 JP 2005533050A5
Authority
JP
Japan
Prior art keywords
formula
group
compound
protected
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004511275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005533050A (ja
JP4607582B2 (ja
Filing date
Publication date
Priority claimed from DE10225574A external-priority patent/DE10225574A1/de
Application filed filed Critical
Publication of JP2005533050A publication Critical patent/JP2005533050A/ja
Publication of JP2005533050A5 publication Critical patent/JP2005533050A5/ja
Application granted granted Critical
Publication of JP4607582B2 publication Critical patent/JP4607582B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004511275A 2002-06-10 2003-05-16 アリールオキシム Expired - Fee Related JP4607582B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10225574A DE10225574A1 (de) 2002-06-10 2002-06-10 Aryloxime
PCT/EP2003/005173 WO2003104205A1 (de) 2002-06-10 2003-05-16 Aryloxime

Publications (3)

Publication Number Publication Date
JP2005533050A JP2005533050A (ja) 2005-11-04
JP2005533050A5 true JP2005533050A5 (cg-RX-API-DMAC7.html) 2006-06-29
JP4607582B2 JP4607582B2 (ja) 2011-01-05

Family

ID=29557700

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004511275A Expired - Fee Related JP4607582B2 (ja) 2002-06-10 2003-05-16 アリールオキシム

Country Status (17)

Country Link
US (2) US7135471B2 (cg-RX-API-DMAC7.html)
EP (1) EP1511737B1 (cg-RX-API-DMAC7.html)
JP (1) JP4607582B2 (cg-RX-API-DMAC7.html)
KR (1) KR20050008817A (cg-RX-API-DMAC7.html)
CN (1) CN1659148A (cg-RX-API-DMAC7.html)
AR (1) AR040251A1 (cg-RX-API-DMAC7.html)
AT (1) ATE457980T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003240259B2 (cg-RX-API-DMAC7.html)
BR (1) BR0311311A (cg-RX-API-DMAC7.html)
CA (1) CA2488934C (cg-RX-API-DMAC7.html)
DE (2) DE10225574A1 (cg-RX-API-DMAC7.html)
ES (1) ES2339646T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA04012211A (cg-RX-API-DMAC7.html)
PL (1) PL371920A1 (cg-RX-API-DMAC7.html)
RU (1) RU2004139233A (cg-RX-API-DMAC7.html)
WO (1) WO2003104205A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200500134B (cg-RX-API-DMAC7.html)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP2532677A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
HRP20120494T1 (hr) 2006-04-21 2012-08-31 Novartis Ag Derivati purina za uporabu kao agonista adenozin a2a receptora
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Pi3k脂質キナーゼ阻害剤としてのピラゾロピリミジン
BRPI0718266A2 (pt) 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
US7978848B2 (en) * 2007-01-09 2011-07-12 Microsoft Corporation Content encryption schema for integrating digital rights management with encrypted multicast
AU2007342223B2 (en) 2007-01-10 2011-02-24 Irm Llc Compounds and compositions as channel activating protease inhibitors
EP2332933A1 (en) 2007-05-07 2011-06-15 Novartis AG Epithelial sodium channel (ENaC) inhibitors
WO2009061516A1 (en) * 2007-11-08 2009-05-14 New York University School Of Medicine Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening
BRPI0820669A2 (pt) 2007-12-10 2020-08-04 Novartis Ag compostos orgânicos
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
KR20110040818A (ko) 2008-06-10 2011-04-20 노파르티스 아게 상피 나트륨 채널 차단제로서의 피라진 유도체
ES2396023T3 (es) 2009-01-29 2013-02-18 Novartis Ag Bencimidazoles sustituidos para el tratamiento de astrocitomas
US8481731B2 (en) * 2009-06-24 2013-07-09 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
US8293729B2 (en) * 2009-06-24 2012-10-23 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
UA111579C2 (uk) 2009-08-17 2016-05-25 Інтеллікіне Ллк ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
IN2012DN01453A (cg-RX-API-DMAC7.html) 2009-08-20 2015-06-05 Novartis Ag
AU2010310449A1 (en) 2009-10-22 2012-05-03 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
CA2817847C (en) * 2010-11-12 2018-02-13 The Johns Hopkins University Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease
US10309974B2 (en) 2010-11-12 2019-06-04 Cedars-Sinai Medical Center Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー N−置換ヘテロシクリルカルボキサミド類
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
CN103946221B (zh) 2011-09-16 2016-08-03 诺华股份有限公司 用于治疗囊性纤维化的杂环化合物
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
MX371119B (es) 2012-04-03 2020-01-17 Novartis Ag Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
HK1219421A1 (zh) 2013-03-15 2017-04-07 因特利凯有限责任公司 激酶抑制剂的组合及其用途
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Mdm2抑制劑與BRAF抑制劑之組合及其用途
KR20160145780A (ko) 2014-04-24 2016-12-20 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체
AU2014391610B2 (en) 2014-04-24 2018-01-25 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
CA2945212A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
US10195208B2 (en) 2014-07-31 2019-02-05 Novartis Ag Combination therapy
EP3268085A4 (en) 2015-03-13 2018-10-31 The Board of Trustees of The Leland Stanford Junior University Ltb4 inhibition to prevent and treat human lymphedema
EP3311176A4 (en) 2015-06-18 2019-03-13 Cedars-Sinai Medical Center ROLE OF CITRULLINATION IN THE DIAGNOSIS OF ILLNESSES
CN107286101B (zh) * 2017-07-27 2020-04-21 云南大学 1-芳醛肟尿嘧啶及其制备方法
US20200383960A1 (en) 2019-06-10 2020-12-10 Novartis Ag Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis
KR20220052934A (ko) 2019-08-28 2022-04-28 노파르티스 아게 치환 1,3-페닐 헤테로아릴 유도체 및 질환 치료에서의 이의 용도
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
CN117558997B (zh) * 2024-01-11 2024-04-02 河南鑫泉能源科技有限公司 一种锂离子电池电解液及其制备方法与电池

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19632549A1 (de) * 1996-08-13 1998-02-19 Merck Patent Gmbh Arylalkanoylpyridazine
DE19826841A1 (de) * 1998-06-16 1999-12-23 Merck Patent Gmbh Arylalkanoylpyridazine
DE19915364A1 (de) * 1999-04-06 2000-10-12 Merck Patent Gmbh Verwendung von Arylalkanoylpyridazinen

Similar Documents

Publication Publication Date Title
NZ598172A (en) Synthesis of boronic ester and acid compounds
JP2005534660A5 (cg-RX-API-DMAC7.html)
TW200621779A (en) Process for the manufacture of dihydropteridinones
PL371582A1 (en) Difluoromethyl thiazolyl carboxanilides
CA2378382A1 (en) Carboxylic acid amides, pharmaceutical compositions containing these compounds, the use and preparation thereof
CA2643067A1 (en) Polyfluoroalkyl alcohol, or (meth)acrylic acid derivative thereof, and process for producing the same
MY146660A (en) Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of nep inhibitors
WO2003046034A3 (en) Improved synthesis of polyanhyrides
CA2504730A1 (en) Cephem compounds
CA2420576A1 (en) Immunoregulatory compounds, derivatives thereof and their use
MX2009005392A (es) Proceso para preparar carboxamidas mediante hidrolisis de carbonitrilos en la presencia de un catalizador que comprende dioxido de manganesio.
WO2007098608A8 (en) Chiral ligands, their preparation and uses thereof in assymetric reactions
AU3759101A (en) Process for the preparation of citalopram
HRP20030566B1 (en) Improved process for carbapenem synthesis
JP2004529172A5 (cg-RX-API-DMAC7.html)
TW200702330A (en) 3,4,5-Substituted piperidines
TR200200745T2 (tr) Fenilasetik asit türevleri için proses.
WO2007017695A3 (en) Dihydroxyanthraquinones and their use
WO2009044409A3 (en) Novel resolution process for pregabalin
TW200716544A (en) Organic compounds
CA2434408A1 (en) Process for the preparation of heterocyclic indene analogs
EP1378502A4 (en) OLIGOLACTIC ACID ESTER WITH CHAIN
IL148161A0 (en) Process for the preparation of 2-cyanopyridines
UA102091C2 (ru) Способ получения сульфонилпиролов как ингибиторов hdac
EP1484311A4 (en) PROCESS FOR PRODUCING A CHAIN OLIGOLACTIC ACID ESTER